No Evidence of Impact on Sperm Motility from Current Literature
Based on the available evidence, there is no documented effect of oral minoxidil on sperm motility in humans. The most recent comprehensive guidelines on oral minoxidil use for hair loss 1, 2 do not list any effects on sperm parameters, including motility, among the known or potential side effects.
What the Evidence Shows
Guideline-Level Evidence
The 2025 international consensus statements and comprehensive reviews on low-dose oral minoxidil (LDOM) for hair loss 1, 2 extensively detail potential side effects including:
- Cardiovascular effects (hypotension, tachycardia, pericardial effusion)
- Hypertrichosis (unwanted hair growth)
- Fluid retention and edema
- Transient hair shedding
Notably absent from these comprehensive safety profiles is any mention of reproductive effects or sperm parameter changes. These guidelines specifically note that oral minoxidil should not be used during pregnancy or breastfeeding 1, but this relates to fetal/infant exposure rather than male fertility concerns.
Research Evidence Limitations
While one 2025 animal study 3 reported testicular structural changes in mice receiving oral minoxidil (2.5-7.5 mg/kg daily), this research has critical limitations:
- Only finasteride (not minoxidil) significantly affected sperm parameters - specifically reducing sperm transit time and cauda sperm count
- The study explicitly states: "only finasteride significantly reduced sperm transit time (at 42 and 84 days) and cauda sperm count (at 84 days)"
- Animal doses used were substantially higher than human therapeutic doses when adjusted for body surface area
- No human clinical data supports these findings
A 2023 systematic review 4 comparing finasteride and minoxidil concluded that finasteride was more harmful to male reproductive health, with minoxidil's effects being less clear and primarily related to oxidative stress in animal models rather than direct sperm motility impairment.
Clinical Bottom Line
For men of reproductive age considering oral minoxidil for hair loss, current evidence does not support concerns about sperm motility impairment. The doses used for alopecia treatment (typically 1.25-5 mg daily) 2 are far below the antihypertensive doses (10-40 mg daily) where systemic effects are more pronounced.
Important Caveats
- Long-term human reproductive safety data for oral minoxidil remains limited 5
- If fertility concerns exist, baseline and follow-up semen analysis could be considered, though this is not standard practice
- The absence of reported effects in extensive clinical use and recent consensus guidelines is reassuring but does not definitively exclude rare or subtle effects
In contrast, finasteride (commonly co-prescribed for hair loss) has documented reproductive effects including reduced semen volume, decreased libido, and potential impacts on sperm parameters 3, 4. If both medications are being considered, this distinction becomes clinically relevant.